Unnecessary test ordering in clinical trials: human chorionic gonadotropin as an example

被引:0
作者
Alegre, Estibaliz [1 ,2 ]
Sanmamed, Miguel F. [2 ,3 ,4 ]
Sendino, Teresa [5 ]
Perez-Gracia, Jose Luis [2 ,3 ,4 ]
机构
[1] Clin Univ Navarra, Biochem Lab, Ave Pio XII 36, Pamplona 31008, Spain
[2] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain
[3] Clin Univ Navarra, Oncol Dept, Pamplona, Spain
[4] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[5] Clin Univ Navarra, Biochem Lab, Pamplona, Spain
来源
ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO | 2020年 / 1卷 / 02期
关键词
clinical trial; chorionic gonadotropin (hCG); HCG; CANCER;
D O I
10.1515/almed-2019-0004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
引用
收藏
页数:2
相关论文
共 5 条
[1]  
Groza D, 2017, BMJ CASE REP, V2017
[3]   β-Human chorionic gonadotropin (HCG) dosage and lung cancer - a pitfall when screening patients for clinical trials [J].
Khobta, Nataliya ;
Tomasini, Pascale ;
Garcia, Marie-Eve ;
Garcia, Stephane ;
Barlesi, Fabrice .
BULLETIN DU CANCER, 2012, 99 (11) :1065-1068
[4]   Establishing reference intervals for hCG in postmenopausal women [J].
Patel, Khushbu K. ;
Qavi, Abraham J. ;
Hock, Karl G. ;
Gronowski, Ann M. .
CLINICAL BIOCHEMISTRY, 2017, 50 (4-5) :234-237
[5]   Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women [J].
Snyder, JA ;
Haymond, S ;
Parvin, CA ;
Gronowski, AM ;
Grenache, DG .
CLINICAL CHEMISTRY, 2005, 51 (10) :1830-1835